“…2 In this issue of Thrombosis and Haemostasis, Souri and colleagues present a detailed biochemical characterization of an anti-FXIII-B alloantibody, which was developed in an FXIII-B-deficient patient as a result of repeated plasmaderived FXIII concentrate substitution therapy. 3 Alloantibody of the patient turned out to be polyclonal as it exhibited binding to several individual Sushi domains of FXIII-B. The alloantibodies did not affect the activity of previously activated FXIII-A, however, inhibited the cleavage of the activation peptide from FXIII-A and fibrin crosslinking in an A 2 B 2 heterotetramer-dependent manner.…”